Explore

Trendline Trendline
TRexBio Presents Data Supporting TNFR2 Agonism for Atopic Dermatitis Treatment

TRexBio Presents Data Supporting TNFR2 Agonism for Atopic Dermatitis Treatment

TRexBio Presents Data Supporting TNFR2 Agonism for Atopic Dermatitis Treatment
Trendline Trendline
Zura Bio Reports Strong Financial Position and Progress in Clinical Trials

Zura Bio Reports Strong Financial Position and Progress in Clinical Trials

Zura Bio Reports Strong Financial Position and Progress in Clinical Trials
Trendline Trendline
Amylyx Pharmaceuticals Advances Avexitide for Post-Bariatric Hypoglycemia with Phase 3 Trial Completion

Amylyx Pharmaceuticals Advances Avexitide for Post-Bariatric Hypoglycemia with Phase 3 Trial Completion

Amylyx Pharmaceuticals Advances Avexitide for Post-Bariatric Hypoglycemia with Phase 3 Trial Completion
Trendline Trendline
Altasciences and Certara Partner to Enhance Early Drug Development with Model-Informed Approaches

Altasciences and Certara Partner to Enhance Early Drug Development with Model-Informed Approaches

Altasciences and Certara Partner to Enhance Early Drug Development with Model-Informed Approaches
Trendline Trendline
TRexBio Unveils Promising Data on TNFR2 Agonism for Atopic Dermatitis at Dermatology Meeting

TRexBio Unveils Promising Data on TNFR2 Agonism for Atopic Dermatitis at Dermatology Meeting

TRexBio Unveils Promising Data on TNFR2 Agonism for Atopic Dermatitis at Dermatology Meeting
Trendline Trendline
Nektar Therapeutics Strengthens Financial Position Amidst Development of Lead Biologic Candidate

Nektar Therapeutics Strengthens Financial Position Amidst Development of Lead Biologic Candidate

Nektar Therapeutics Strengthens Financial Position Amidst Development of Lead Biologic Candidate
Trendline Trendline
Evommune Reports Q1 2026 Financial Results and Advances Inflammatory Disease Therapies

Evommune Reports Q1 2026 Financial Results and Advances Inflammatory Disease Therapies

Evommune Reports Q1 2026 Financial Results and Advances Inflammatory Disease Therapies
Trendline Trendline
Incyte Releases Positive Long-Term Data for Opzelura Cream in Atopic Dermatitis Treatment

Incyte Releases Positive Long-Term Data for Opzelura Cream in Atopic Dermatitis Treatment

Incyte Releases Positive Long-Term Data for Opzelura Cream in Atopic Dermatitis Treatment
Trendline Trendline
Incyte Releases Positive 24-Week Data for Opzelura Cream in Atopic Dermatitis Treatment

Incyte Releases Positive 24-Week Data for Opzelura Cream in Atopic Dermatitis Treatment

Incyte Releases Positive 24-Week Data for Opzelura Cream in Atopic Dermatitis Treatment
Trendline Trendline
Kanvas Biosciences Secures $48M to Enhance Spatial Biology and Cancer Trials

Kanvas Biosciences Secures $48M to Enhance Spatial Biology and Cancer Trials

Kanvas Biosciences Secures $48M to Enhance Spatial Biology and Cancer Trials
Trendline Trendline
Pierre Fabre Pharmaceuticals Aligns with FDA for Tabelecleucel BLA Resubmission

Pierre Fabre Pharmaceuticals Aligns with FDA for Tabelecleucel BLA Resubmission

Pierre Fabre Pharmaceuticals Aligns with FDA for Tabelecleucel BLA Resubmission
Trendline Trendline
Scholar Rock Advances Apitegromab for SMA with FDA Approval Milestone

Scholar Rock Advances Apitegromab for SMA with FDA Approval Milestone

Scholar Rock Advances Apitegromab for SMA with FDA Approval Milestone